Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $144,189.08 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Stephen B. Shohet sold 7,862 shares of the company’s stock in a transaction dated Thursday, October 19th. The stock was sold at an average price of $18.34, for a total value of $144,189.08. Following the completion of the sale, the director now owns 31,978 shares in the company, valued at approximately $586,476.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) remained flat at $18.41 during mid-day trading on Friday. The stock had a trading volume of 126,448 shares. Amphastar Pharmaceuticals, Inc. has a 52-week low of $12.05 and a 52-week high of $21.75. The stock has a market capitalization of $850.45 million, a PE ratio of 239.09 and a beta of 1.69. The stock has a 50 day moving average of $17.58 and a 200 day moving average of $16.58.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 9th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.05. The firm had revenue of $65.20 million during the quarter, compared to analysts’ expectations of $63.40 million. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The business’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.23 earnings per share. Equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post $0.27 EPS for the current fiscal year.

Amphastar Pharmaceuticals declared that its board has authorized a stock buyback plan on Wednesday, August 9th that authorizes the company to repurchase $20.00 million in shares. This repurchase authorization authorizes the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

WARNING: “Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $144,189.08 in Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/stephen-b-shohet-sells-7862-shares-of-amphastar-pharmaceuticals-inc-amph-stock.html.

A number of brokerages have commented on AMPH. Piper Jaffray Companies set a $19.00 price target on Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $19.00 price target (down previously from $20.00) on shares of Amphastar Pharmaceuticals in a report on Friday, August 11th. Zacks Investment Research cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Needham & Company LLC raised their target price on Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, September 27th. Finally, ValuEngine lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $20.29.

Institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after buying an additional 842 shares during the period. SG Americas Securities LLC acquired a new position in shares of Amphastar Pharmaceuticals in the second quarter valued at approximately $111,000. Municipal Employees Retirement System of Michigan boosted its holdings in shares of Amphastar Pharmaceuticals by 3.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 8,200 shares of the company’s stock valued at $119,000 after buying an additional 290 shares during the period. Mason Street Advisors LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 8,394 shares of the company’s stock valued at $122,000 after buying an additional 549 shares during the period. Finally, State of Alaska Department of Revenue boosted its holdings in shares of Amphastar Pharmaceuticals by 77.2% in the second quarter. State of Alaska Department of Revenue now owns 7,052 shares of the company’s stock valued at $125,000 after buying an additional 3,072 shares during the period. Institutional investors own 44.04% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply